EGFR MUTATION ANALYSIS (Targeted Therapy Gene Test)
(Flat ₹1001 OFF - Sanovra Lab)
Report Time: 7th Working Day (Cutoff 4:30 PM) | Sample: Tissue Biopsy (FFPE Block) | Test Code: MC056
EGFR (Epidermal Growth Factor Receptor) is a protein found on the surface of cells that helps them grow and divide. However, in some cancers most notably Non-Small Cell Lung Cancer (NSCLC) the gene controlling this protein is mutated. This mutation acts like a broken on switch, causing the cancer cells to multiply uncontrollably.
The EGFR Mutation Analysis is a highly advanced molecular genetics test that scans the tumor's DNA to find these specific mutations. Knowing the mutation status is the cornerstone of modern precision oncology, allowing doctors to prescribe highly effective Targeted Therapies.
The Power of Targeted Therapy
Historically, lung cancer was treated with standard Chemotherapy, which aggressively attacks all fast-growing cells in the body, leading to severe side effects (hair loss, severe nausea, immune suppression).
If a patient tests Positive for an EGFR mutation, they can bypass traditional chemotherapy and take Tyrosine Kinase Inhibitors (TKIs) medications (like Erlotinib, Gefitinib, or Osimertinib) taken as a daily pill. These drugs specifically target and shut down the mutated EGFR protein, starving the cancer cells without harming the rest of the body. This significantly improves survival rates and quality of life.
Who Should Get This Test?
Major global oncology guidelines (like NCCN and ASCO) mandate this test for:
-
➤Newly Diagnosed Patients: Anyone diagnosed with advanced, metastatic, or non-squamous Non-Small Cell Lung Cancer (NSCLC).
-
➤Relapsed Patients: Patients whose lung cancer has returned or stopped responding to previous treatments (to check for acquired resistance mutations).
-
➤Non-Smokers: EGFR mutations are particularly common in patients who have never smoked, especially women of Asian descent.
Interpreting Your Results
The lab extracts DNA from the tumor sample and sequences specific segments (Exons 18, 19, 20, and 21) of the EGFR gene.
| Test Result | Clinical Interpretation |
|---|---|
| Positive (Sensitizing Mutation) e.g., Exon 19 Deletion or L858R |
The tumor is driven by EGFR. The patient is an excellent candidate for first-line EGFR targeted therapies (TKIs). |
| Positive (Resistance Mutation) e.g., T790M |
Often seen in patients who were already on TKI therapy but the cancer evolved. Indicates the need to switch to a 3rd-generation TKI (like Osimertinib). |
| Negative (Wild-Type) | No EGFR mutation detected. EGFR inhibitors will likely not work. The oncologist will explore other options like Immunotherapy, Chemotherapy, or test for other gene mutations (ALK, ROS1). |
Frequently Asked Questions (FAQs)
This is a complex molecular biology procedure. The lab must first extract microscopic amounts of DNA from a solid piece of wax-embedded tissue, purify it, amplify it using PCR, and then sequence the genetic code. Accuracy is paramount and takes time.
If a surgical biopsy is impossible or the previous sample is exhausted, doctors may request a "Liquid Biopsy" (ctDNA blood test). This looks for cancer DNA floating in the bloodstream, though tissue remains the gold standard.
While metastatic lung cancer is rarely "cured," targeted therapy turns it into a manageable chronic disease for many patients. The pills shrink the tumors and keep them suppressed for years with far fewer side effects than chemotherapy.
Precision Medicine Starts Here
Unlock the most effective, personalized treatment plan for lung cancer. Submit your tissue block for EGFR Mutation Analysis at Sanovra Lab.
Disclaimer: The information provided here is for educational purposes only and does not constitute medical advice. Genomic testing and cancer treatment plans must be guided by a qualified Medical Oncologist.